ORGANIZATION

Savings from Off-Year Drug Re-Pricing Should Go Towards Medical Fees: JMA Chief

By Takashi Ohama July 15, 2022

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

As Japan gears up for full debates on next year’s “off-year” drug re-pricing, Kichiro Matsumoto, new president of the Japan Medical Association (JMA), renewed the group’s call on July 14 for directing savings from such price cuts towards boosting physician…

To read the full story

Pharma Eyes Riveted on JMA’s Stance on Off-Year Revision as New Chief Builds Ties with Govt
August 22, 2022
Kichiro Matsumoto Elected as New Chief of Japan Medical Association
June 27, 2022

ORGANIZATION

EFPIA Report Calls Japan a “Cautionary Tale” in 10-Country Biopharma Strategy Review
March 2, 2026
Pharma Takes Harsh View of FY2026 Pricing Reform: Policy Group Survey
February 24, 2026
JPMA to Push Govt to Scrap Market-Based Drug Price Revisions
February 20, 2026
Pharma Group Looks to Growth Strategy under Takaichi after Election Win
February 10, 2026
Pharma Groups Call for Faster Diagnosis and R&D for Intractable, Rare Diseases
February 9, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

ICH Weighs Need for Biosimilar Efficacy Trials as Regulators Move Away from Routine Use

By Takashi Ebisawa

International regulators are increasingly moving away from comparative efficacy studies (CES) in biosimilar development — long considered a default requirement…

COLUMN

The Strategic MSL: Beyond Data Delivery, It’s About Impact

By Philip Carrigan

I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…